Hopp L: Talk to Me About Evidence-based Practice!, 17(3):250

J

Jacobi J See Powers J

Jacobson C: Tools for Teaching Arrhythmias: Wide QRS Beats and Rhythms, 17(3):353

Jacobson C: Tools for Teaching Arrhythmias: Wide QRS Beats and Rhythms—Part I; P Waves, Fusion, and Capture Beats, 17(4):462

Jacobson C: Tools for Teaching Arrhythmias, 17(2):230

Johnson KL, Renn C: The Hypothalamic-Pituitary-Adrenal Axis in Critical Illness, 17(1):39

K

Kleinpell RM, Graves BT, Ackerman MH: Incidence, Pathogenesis, and Management of Sepsis: An Overview, 17(4):385

L

Larison K See Dixon JF

M

Makic MBF See Holden M Massey HT See Shannon D Mick DJ See Ackerman MH Morton PG See Dorsey SG

N

Ninni S See Reilly L

O

O'Connor CA See Dakin CL

P

Palmer S See Bader MK

Paniagua-Ramirez CT See Barone CP

Papathanassoglou EDE, Giannakopoulou MD, Bozas E: Genomic Variations and Susceptibility to Sepsis, 17(4):394

Parbhop SK See Gearhart MM

Patsdaughter CA See Dakin CL

Posa PJ, Harrison D, Vollman KM: Elimination of Central Line~associated Bloodstream Infections: Application of the Evidence, 17(4):446

Powers J, Jacobi J: Pharmacologic Treatment Related to Severe Sepsis, 17(4):423

R

Rauen JA, Rauen CA:A Patient's Bold Voice: A Journey Through Cardiac Surgery, 17(2):133

Rauen CA See Rauen JA

Reilly L, Sullivan P, Ninni S, Fochesto D, Williams K, Fetherman B: Reducing Foley Catheter Device Days in the Intensive Care Unit: Using the Evidence to Change Practice, 17(3):272

Renn C See Johnson KL

Rose L:Advanced Modes of Mechanical Ventilation: Implications for Practice, 17(2):145

Rushton CH: Donation After Cardiac Death: Ethical Implications and Implementation Strategies, 17(3):345

Rushton CH: Defining and Addressing Moral Distress: Tools for Critical Care Nursing Leaders, 17(2):161

5

Selig PM: Metabolic Syndrome in the Acute Care Setting, 17(1):79

Shannon D, Hallinan W, Massey HT, Ackerman MH: Mechanical Circulatory Assist Devices, 17(4):368 Sullivan P See Reilly L

T

Thornby D: Beginning the Journey to Skilled Communication, 17(3):266 Trimarchi T: Endocrine Problems in Critically III Children: An Overview, 17(1):66

V

Vollman KM See Posa PJ

W

Williams K See Reilly L

Z

Zabari M See Dixon JF

## 2006 Subject Index

A

Aberrant conduction, (3):353

Accessory pathway conduction, (3):353

Advanced practice nursing

clinical nurse specialist's role, (4):373 coding and reimbursement, (2):116 evidence-based practice, (3):250

Airway pressure release ventilation (APRV), (2):145

American Association of Critical Care Nurses, AACN Standards for Establishing and Sustaining Healthy Work Environments: A Journey to Excellence, (2):119

Antiblotic therapy, in sepsis, (4):423

Aortic valve replacement, patient's perspective, (2):133

Apoptosis, genomic variations and susceptibility to sepsis, (4):394

Arrhythmias

dofetilide therapy, (2):102

ECG challenges, ladder diagram, (2):230 wide QRS beats and rhythms, (3):353

waves, fusion, and capture beats, (4):462

Artificial heart, (4):368

Asthma, acute severe, mechanical ventilation, (2):186

Atracurium (Tracrium), (3):239

Atrial fibrillation/flutter, dofetilide therapy, (2):102

Atrioventricular dissociation, (4):462

Auto-PEEP, in acute severe asthma, (2):186

Autoregulation, in critically ill neuroscience patient, (3):327

B

Base deficit, resuscitation endpoint, (3):306

Bedside researchers, (3):253

Biphasic positive airway pressure (BIPAP) ventilation, (2):145

Blood pressure, monitoring, for sepsis, (2):215

Blood pumps, (4):368

Bloodstream infection, central line-associated, (4):446 Book reviews

Burns, S.: AACN Protocols for Practice: Noninvasive Monitoring, 2nd ed., (2):224

Burns, S. (ed.): AACN Protocols for Practice: Care of Mechanically Ventilated Patients, 2nd ed., (4):460

Brain injury. See Critically ill neuroscience patient

C

Capture beats, ECG challenge, (4):462

Cardiac arrest, postresuscitation care, (2):125

Cardiac death, organ donation after, (3):345

Cardiac surgery, patient's perspective, (2):133

Catheters/catheterization

indwelling urinary catheters, (3):272 pulmonary artery pressure monitoring, (3):286

Central line-associated bloodstream infections, prevention, (4):446

Cerebral blood flow, in critically ill neuroscience patient, (3):327

Cerebral hypoxia, in critically ill neuroscience patient, (3):327

Cerebral perfusion pressure, in critically ill neurosciente patient, (3):327

Change process models, moral distress, (2):161

Circus movement tachycardia, (3):353

Cisatracurium (Nimbex), (3):239

Clinical nurse specialist, (4):373

Clinician researchers, (3):253

Closed-loop ventilation, (2):145

Coagulation/fibrinolysis pathways, genomic variations and susceptibility to sepsis, (4):394

Coding, (2):116

Collaboration, healthy work environment, (2):119

Communication

healthy work environment, (2):119

skilled

beginning the journey, (3):266 making it work, (4):376

Complex systems theory, genomic variations and susceptibility to sepsis, (4):394

Conflict, skilled communication, (3):266

Congestive heart failure, evidence-based nursing care, (2):170

Continuing education

advanced modes of mechanical ventilation, (2):145 central line-associated bloodstream infections, (4):446 evidence-based heart failure nursing care, (2):170 pharmacologic treatment in severe sepsis, (4):423

pulmonary artery pressure monitoring, (3):286 sustained neuromuscular blockade, (3):239 update of dofetilide (Tikosyn) therapy, (2):102

Corticosteroids, in sepsis, (4):423

Critical care nursing

continuous physiologic monitoring for sepsis, (2):215 Foley catheter use, (3):272 moral distress, (2):161

Critically ill neuroscience patient, hemodynamic monitoring, (3):327

Crucial conversations, skilled communication, (3):266 Culture of silence, (3):266

Cytokines, genomic variations and susceptibility to sepsis, (4):394

D

Decision-making, healthy work environment, (2):119 Dofetilide (Tikosyn), (2):102

Doppler technique, hemodynamic monitoring in sepsis, (4):435 Drotrecogin alpha activated (Xigris), in sepsis, (4):423

Drug interactions, sustained neuromuscular blockade, (3):239

Drug update

dofetilide (Tikosyn) therapy, (2):102 recombinant factor VIIa in neuroscience, (4):364 sustained neuromuscular blockade, (3):239

Dynamic hyperinflation, in acute severe asthma, (2):186

ł

Economic issues, coding and reimbursement, (2):116 Education, arrhythmias

ladder diagram, (2):230

wide QRS beats and rhythms, (3):353, (4):462

Electrocardiography, arrhythmias

ladder diagram, (2):230

wide QRS beats and rhythms, (3):353 waves, fusion, and capture beats, (4):462

Enteral feeding tube, placement, verification, (3):246 Ethical issues

moral distress, (2):161

organ donation after cardiac death, (3):345

Evidence-based practice, (3):250

central line-associated bloodstream infections, prevention, (4):446

prevention, (4):446 clinically induced hypothermia, (2):125

continuous physiologic monitoring for sepsis, (2):215

Foley catheter use, (3):272 heart failure, (2):170

hyperacute stroke, (2):194

research, quality improvement and, (4):457

sepsis management, 385

ventilation in acute severe asthma, (2):186

F

Factor V, genomic variations and susceptibility to sepsis, (4):394

Feeding tube, placement, verification, (3):246

Fluid resuscitation, in sepsis, (4):435

Functional hemodynamics, pulmonary artery pressure monitoring, (3):286

Fusion, ECG challenge, (4):462

C

Gastric tonometry, resuscitation endpoints, (3):306 Genetics, genomic variations and susceptibility to sepsis, (4):394

н

Healthy workplace

AACN standards, (2):119 communication, (3):266

skilled communication, making it real, (4):376

Heart failure

evidence-based nursing care, (2):170 mechanical circulatory assist devices, (4):368

Heart rate, monitoring, for sepsis, (2):215

Heat shock proteins, genomic variations and susceptibility to sepsis, (4):394

Hemodynamic monitoring

critically ill neuroscience patient, (3):327 endpoints of resuscitation, (3):306 pulmonary artery pressure monitoring, (3):286 in sepsis, (4):435

traumatic shock, (3):317

Hospital-acquired infections, central line-associated bloodstream infections, (4):446

Hyperacute stroke, recombinant tissue plasminogen activator (rtPA) in, (2):194

Hypertension, in critically ill neuroscience patient, (3):327

Hypothermia, clinically induced, (2):125

Hypovolemia, in traumatic shock, (3):317

I

Infection

central line-associated bloodstream infections, (4):446 urinary tract, catheter-associated, (3):272

Inotropic agents, in sepsis, (4):423

Insulin therapy, in sepsis, (4):423

Interleukin(s), genomic variations and susceptibility to sepsis, (4):394

Intracerebral hemorrhage, recombinant factor VIIa in, (4):363 Intraceranial pressure, in critically ill neuroscience patient, (3):327

Ischemic stroke

recombinant factor VIIa in, (4):363 recombinant tissue plasminogen activator (rtPA) in, (2):194

L

Lactate, blood levels

resuscitation endpoint, (3):306 in sepsis, (4):435

Ladder diagram, tools for teaching arrhythmias, (2):230

M

Mannose-binding lectin, genomic variations and susceptibility to sepsis, (4):394

Mechanical circulatory assist devices, (4):368

Mechanical ventilation

in acute severe asthma, (2):186 advanced modes, (2):145 Monitoring

continuous physiologic monitoring for sepsis, (2):215 hemodynamic. See Hemodynamic monitoring

Moral distress, (2):161

N

Neurologic outcome, clinically induced hypothermia, (2):125

Neuromuscular blockade, sustained, (3):239

Neuronal injury, secondary, prevention, (3):327 Nursing care, evidence-based. See Evidence-based practice

Nursing leadership, moral distress, (2):161

Nursing research. See Research

0

Organ donation, after cardiac death, (3):345 Oxygen delivery/consumption, resuscitation endpoint, (3):306

P

Pancuronium (Pavulon), (3):239

Patient's perspective, aortic valve replacement, (2):133

Pediatric population, mechanical circulatory assist devices, (4):368

Performance improvement, central line-associated bloodstream infections, (4):446

Performance measures, evidence-based heart failure nutsing care, (2):170

Perfusion, endpoints of resuscitation, (3):306

Pharmacology, in sepsis, (4):423

Physiologic monitoring, continuous, for sepsis, (2):215

Polymorphisms, sepsis-susceptibility, (4):394

Pulmonary artery pressure, monitoring, (3):286

P waves, ECG challenge, (4):462

Q

QRS complex, wide QRS beats and rhythms, (3):353 waves, fusion, and capture beats, (4):462

Quality improvement

evidence-based heart failure nursing care, (2):170 research, evidence-based practice and, (4):457

R

Recombinant factor VIIa (NovoSeven), in neuroscience, (4):363

Recombinant tissue plasminogen activator (rtPA), in hyperacute stroke, (2):194

Research

clinically relevant questions, (3):253 evidence-based practice, quality improvement and, (4):457 generating interest in nursing research, (2):226 sample size estimation, (3):341

Respiratory rate, monitoring, for sepsis, (2):215

Resuscitation, traumatic shock, (3):317

Resuscitation, traumatic snock, (3):31/

5

Sepsis

central line-associated bloodstream infections, (4):446 continuous physiologic monitoring, (2):215

genomic variations and susceptibility to, (4):394 hemodynamic monitoring, (4):435 incidence, pathogenesis, and management, (4):385 severe, pharmacologic treatment, (4):423

Shivering, clinically induced hypothermia, (2):125 Shock

resuscitation endpoints, (3):306 septic, (4):423 traumatic, (3):317

Skilled communication

beginning the journey, (3):266 making it real, (4):376

Spectroscopy, near-infrared, resuscitation endpoints, (3):306 Spinal cord injury. See Critically ill neuroscience patient Staffing, healthy work environment, (2):119

Stress hormones, genomic variations and susceptibility to sepsis, (4):394

Stroke

hyperacute, recombinant tissue plasminogen activator (rtPA) in, (2):194

recombinant factor VIIa in, (4):363

Stroke index, in sepsis, (4):435

Sublingual capnometry, resuscitation endpoints, (3):306

T

Technology

enteral feeding tube placement, verification, (3):246 mechanical circulatory assist devices, (4):368 technology assessment primer, (2):111

Temperature, monitoring, for sepsis, (2):215

Tissue oxygenation, endpoints of resuscitation, (3):306

Toll-like receptors, genomic variations and susceptibility to sepsis, (4):394

Transplantation, organ donation after cardiac death, (3):345

Traumatic shock, resuscitation, (3):317

Tumor necrosis factor(s), genomic variations and susceptibility to sepsis, (4):394

U

Urinary catheters, Foley catheter use, (3):272 Urinary tract infection, catheter-associated, (3):272

V

Valve replacement, patient's perspective, (2):133

Vasopressors, in sepsis, (4):423

Vasospasm, cerebral, in critically ill neuroscience patient, (3):327

Venous oxygen saturation, mixed, resuscitation endpoint, (3):306

Venous oxyhemoglobin, mixed, in sepsis, (4):435 Ventilation, assisted. See Mechanical ventilation Ventricular assist devices, (4):368 Vercuronium (Norcuron), (3):239

W

Weaning, mechanical ventilation, (2):145 Wolff-Parkinson-White syndrome, (3):353

STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION (Act of August 12, 1970; Section 3685; Title 39 United States Code) Date of Filing-October 1, 2006. Title of Publication-AACN: Advanced Critical Care; Frequency of Issue-Quarterly; Annual Subscription Price-\$85.00; Location of Known Office of Publication-Lippincott Williams & Wilkins, Inc., 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116; Location of the Headquarters or General Business Offices of the Publisher-Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Publisher-Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Editor-Marianne Chulay, RN, DNSc, FAAN, 505 N. Boundary St., Chapel Hill, NC 27514. Managing Editor-Randi Davis, Lippincott Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106; Owner-American Association of Critical-Care Nurses, 101 Columbia, Aliso Viejo, CA 92656; Known Bond Holders, Mortgagees, and other security holders owning or holding 1 percent or more of the total amount of bonds, mortgages, or other securities-None. A. Total no. of copies printed (net press run), average 2,425, actual 2,300. B. Paid and/or requested circulation 1. Paid/requested outside-county mail subscriptions stated on form 3541, average 1,332, actual 1,366; 2. Paid in county subscriptions, none; 3. Sales through dealers and carriers. street vendors, counter sales, and other non-USPS paid distribution, average 74, actual 80; 4. Other classes mailed through the USPS, none. C. Total paid and/or requested circulation [sum of B (1), (2), (3), and (4)], average 1,406, actual 1,446. D. Free distribution by mail (samples, complimentary, and other free). Outside-county as stated on form 3541, average 54, actual 265; 2. In-county as stated on form 3541, none; 3. Other classes mailed through the USPS, none. E. Free distribution outside the mail (carriers or other means), average 2, actual 12. F. Total free distribution (sum of D and E), average 56, actual 277. G. Total distribution (sum of C and F), average 1,462, actual 1,723. H. Copies not distributed, average 963, actual 577. I. Total (sum of G and H), average 2,425. actual 2,300. Percent paid and/or requested circulation, average 96.17%, actual 83.92%. I certify that the statements made by me above are correct and complete. Jeffrey Brown, Manager, Periodicals Operations.

i.

it. C 66; ad of F. ee-